Theriva Biologics: No Material Development to Account for Stock Activity

Dow Jones

Oct 25

By Josh Beckerman

Theriva Biologics, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action.

The company added that there wasn't any material development in its business and affairs not previously disclosed.

Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said.

The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares.

On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 24, 2025 15:01 ET (19:01 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578428995"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578428995\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578428995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-25 03:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578428995","market":"sg","top_or_hot":-1,"title":"Theriva Biologics: No Material Development to Account for Stock Activity","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a>, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action. \n</p>\n<p>\n  The company added that there wasn't any material development in its business and affairs not previously disclosed. \n</p>\n<p>\n  Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said. \n</p>\n<p>\n  The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares. \n</p>\n<p>\n  On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 15:01 ET (19:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Theriva Biologics: No Material Development to Account for Stock Activity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTheriva Biologics: No Material Development to Account for Stock Activity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-25 03:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a>, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action. \n</p>\n<p>\n  The company added that there wasn't any material development in its business and affairs not previously disclosed. \n</p>\n<p>\n  Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said. \n</p>\n<p>\n  The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares. \n</p>\n<p>\n  On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 24, 2025 15:01 ET (19:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578428995","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578428995","pubTimestamp":1761332460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Theriva Biologics, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action.The company added that there wasn't any material development in its business and affairs not previously disclosed.Theriva's response to the unusual market action was pursuant to Section 401 of the NYSE Company Guide, it said.The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares.On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TOVX":"Theriva Biologics"},"translate_title":"Theriva Biologics：没有重大开发来解释库存活动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOVX":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nTheriva Biologics, whose shares rose sharply Friday, said there has been no reason to account for the unusual market action. \n\n\n  The company added that there wasn't any material development in its business and affairs not previously disclosed. \n\n\n  Theriva's response to the unusual market action was pursuant to Section 401(d) of the NYSE Company Guide, it said. \n\n\n  The stock was recently up 44%, to 49 cents, on volume of more than 479 million shares, compared with a 65-day average of 4.9 million shares. \n\n\n  On Monday, expanded metastatic pancreatic ductal adenocarcinoma data from Theriva's VIRAGE Phase 2b trial was presented at the European Society for Medical Oncology Annual Congress. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 24, 2025 15:01 ET (19:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}